Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Camurus AB ( (SE:CAMX) ) has issued an update.
Camurus AB reported significant financial growth in the third quarter of 2025, with total revenues increasing by 18% to SEK 567 million and profit before tax rising by 48% to SEK 245 million. The company achieved notable milestones, including the UK approval of Oczyesa® for acromegaly treatment and orphan drug designations for CAM2029 in the US and Europe. Despite lowering its revenue guidance for 2025, Camurus maintained its profit forecast, reflecting strong operational performance and strategic positioning in the biopharmaceutical industry.
The most recent analyst rating on (SE:CAMX) stock is a Hold with a SEK718.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus AB is a global biopharmaceutical company focused on developing and commercializing long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus has a robust R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. The company operates in Europe, the US, and Australia, with headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 76,262
Technical Sentiment Signal: Hold
Current Market Cap: SEK36.57B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.